Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Vaibhav Sahai, MD
University of Michigan Health System in Ann Arbor, MI
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical University of Vienna
Vienna, Austria
- Colorado Cancer Research Program
Denver, Colorado, United States
- Northwestern University
Chicago, Illinois, United States
- Advocate Christ Medical Center
Oak Lawn, Illinois, United States
- Siouxland Hematology-Oncology Associates
Sioux City, Iowa, United States
- Ochsner Medical Center
New Orleans, Louisiana, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- University Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
- St. Joseph Mercy Health System
Ann Arbor, Michigan, United States
- University of Michigan Health System
Ann Arbor, Michigan, United States
- University of Michigan Medical Center
Ann Arbor, Michigan, United States
- Metro Minnesota Ccop
Saint Louis Park, Minnesota, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Mount Sinai Hospital
New York, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pennsylvania; Abramson Cancer Center at Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
- University of Tennessee Medical Center
Knoxville, Tennessee, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- Gundersen Health System
La Crosse, Wisconsin, United States
- University of Wisconsin-Madison
Madison, Wisconsin, United States
- Aurora Cancer Care
Wauwatosa, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Dec 2014
- Primary completion
- 24 Sept 2016
- Completion
- 1 Oct 2017
- Last update posted
- 3 Oct 2018
- Registered enrollment
- 74
- Registry id
- NCT02181634
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.